Literature DB >> 35368589

Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-hydroxylase and Inhibited by Some PHD Inhibitors.

Vijesh J Bhute1, James Harte2,3, Jack W Houghton1, Patrick H Maxwell1.   

Abstract

Background: Mannose-binding lectin (MBL) is an important component of innate immune defense. MBL undergoes oligomerization to generate high mol weight (HMW) forms which act as pattern recognition molecules to detect and opsonize various microorganisms. Several post-translational modifications including prolyl hydroxylation are known to affect the oligomerization of MBL. Yet, the enzyme(s) which hydroxylate proline in the collagen-like domain residues have not been identified and the significance of prolyl hydroxylation is incompletely understood.
Methods: To investigate post-translational modifications of MBL, we stably expressed Myc-DDK tagged MBL in HEK293S cells. We used pharmacologic and genetic inhibition of 2-oxoglutarate-dependent dioxygenases (2OGDD) to identify the enzyme required for prolyl hydroxylation of MBL. We performed mass spectrometry to determine the effects of various inhibitors on MBL modifications.
Results: Secretion of HMW MBL was impaired by inhibitors of the superfamily of 2OGDD, and was dependent on prolyl-4-hydroxylase subunit α1. Roxadustat and vadadustat, but not molidustat, led to significant suppression of hydroxylation and secretion of HMW forms of MBL. Conclusions: These data suggest that prolyl hydroxylation in the collagen-like domain of MBL is mediated by collagen prolyl-4-hydroxylase. Reduced MBL activity is likely to be an off-target effect of some, but not all, prolyl hydroxylase domain (PHD) inhibitors. There may be advantages in selective PHD inhibitors that would not interfere with MBL production.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  FG-4592; HEK293 cells; PHD inhibitors; chronic kidney disease; collagen prolyl-4-hydroxylase; hypoxia inducible factor; mannose binding lectin; post-translational; protein processing; renal anemia; vadadustat; molidustat

Mesh:

Substances:

Year:  2020        PMID: 35368589      PMCID: PMC8809307          DOI: 10.34067/KID.0000092020

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  38 in total

Review 1.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  The two major oligomeric forms of human mannan-binding lectin: chemical characterization, carbohydrate-binding properties, and interaction with MBL-associated serine proteases.

Authors:  Florence Teillet; Bernard Dublet; Jean-Pierre Andrieu; Christine Gaboriaud; Gérard J Arlaud; Nicole M Thielens
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation.

Authors:  E Berra; D E Richard; E Gothié; J Pouysségur
Journal:  FEBS Lett       Date:  2001-02-23       Impact factor: 4.124

4.  Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury.

Authors:  Mary C Walsh; Todd Bourcier; Kazue Takahashi; Lei Shi; Marc N Busche; Russell P Rother; Scott D Solomon; R Alan B Ezekowitz; Gregory L Stahl
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

5.  Posttranslational modifications in human plasma MBL and human recombinant MBL.

Authors:  Pia Hønnerup Jensen; Inga Laursen; Finn Matthiesen; Peter Højrup
Journal:  Biochim Biophys Acta       Date:  2007-01-03

6.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.

Authors:  Nan Chen; Chuanming Hao; Xiaomei Peng; Hongli Lin; Aiping Yin; Li Hao; Ye Tao; Xinling Liang; Zhengrong Liu; Changying Xing; Jianghua Chen; Laimin Luo; Li Zuo; Yunhua Liao; Bi-Cheng Liu; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

7.  A new approach to treating renal anaemia.

Authors:  Patrick H Maxwell
Journal:  Nat Rev Nephrol       Date:  2019-12       Impact factor: 28.314

8.  Connecting genetic risk to disease end points through the human blood plasma proteome.

Authors:  Karsten Suhre; Matthias Arnold; Aditya Mukund Bhagwat; Richard J Cotton; Rudolf Engelke; Johannes Raffler; Hina Sarwath; Gaurav Thareja; Annika Wahl; Robert Kirk DeLisle; Larry Gold; Marija Pezer; Gordan Lauc; Mohammed A El-Din Selim; Dennis O Mook-Kanamori; Eman K Al-Dous; Yasmin A Mohamoud; Joel Malek; Konstantin Strauch; Harald Grallert; Annette Peters; Gabi Kastenmüller; Christian Gieger; Johannes Graumann
Journal:  Nat Commun       Date:  2017-02-27       Impact factor: 14.919

9.  Genomic atlas of the human plasma proteome.

Authors:  Benjamin B Sun; Joseph C Maranville; James E Peters; David Stacey; James R Staley; James Blackshaw; Stephen Burgess; Tao Jiang; Ellie Paige; Praveen Surendran; Clare Oliver-Williams; Mihir A Kamat; Bram P Prins; Sheri K Wilcox; Erik S Zimmerman; An Chi; Narinder Bansal; Sarah L Spain; Angela M Wood; Nicholas W Morrell; John R Bradley; Nebojsa Janjic; David J Roberts; Willem H Ouwehand; John A Todd; Nicole Soranzo; Karsten Suhre; Dirk S Paul; Caroline S Fox; Robert M Plenge; John Danesh; Heiko Runz; Adam S Butterworth
Journal:  Nature       Date:  2018-06-06       Impact factor: 49.962

Review 10.  Oxygen sensing by HIF hydroxylases.

Authors:  Christopher J Schofield; Peter J Ratcliffe
Journal:  Nat Rev Mol Cell Biol       Date:  2004-05       Impact factor: 94.444

View more
  1 in total

Review 1.  Roxadustat: Not just for anemia.

Authors:  Xiaoyu Zhu; Lili Jiang; Xuejiao Wei; Mengtuan Long; Yujun Du
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.